We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Eli Lilly, GE Aerospace and Amgen
Read MoreHide Full Article
For Immediate Release
Chicago, IL – May 23, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Eli Lilly and Co. (LLY - Free Report) , GE Aerospace (GE - Free Report) and Amgen Inc. (AMGN - Free Report) .
Here are highlights from Thursday’s Analyst Blog:
Top Analyst Reports for Eli Lilly, GE Aerospace and Amgen
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Co., GE Aerospace and Amgen Inc.. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
The daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens and attempts to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.
Shares of Eli Lilly have declined -10.9% over the past year versus the Zacks Large Cap Pharmaceuticals industry's decline of -14.7%. The company's Q1 earnings missed estimates while sales beat. Demand for popular GLP-1 drugs Mounjaro and Zepbound remains strong, making them the company's key top-line drivers.
Though sales were below expectations in the second half of 2024, they picked up in the first quarter, driven by launches of the drugs in new international markets, and improved supply from ramped-up production. In the past two years, Lilly received approvals for some new drugs like Kisunla, Omvoh and Jaypirca, which are also contributing to its top-line growth.
Lilly is also making rapid pipeline progress in obesity and diabetes. Declining sales of Trulicity, rising pricing pressure on some drugs and potential competition in the GLP-1 diabetes/obesity market are some top-line headwinds.
GE Aerospace's shares have outperformed the Zacks Aerospace - Defense industry over the past year (+41.3% vs. +12.9%). The company has been witnessing strength in its businesses, driven by robust demand for commercial engines, propulsion and additive technologies. Rising U.S. & international defense budgets, geopolitical tensions, positive airline & airframer dynamics and robust demand for commercial air travel augur well for the company.
Portfolio-reshaping actions are likely to unlock values for its shareholders. The company raised its dividend by 28.6% to 36 cents per share in February 2025. For 2025, GE Aerospace expects organic revenues to grow in the low-double-digit range from the year-ago level.
However, it has been dealing with high costs and expenses related to certain projects and restructuring activities, which are likely to affect margins and profitability. Also, foreign exchange headwinds might be a concern for the company.
Shares of Amgen have declined -8.7% over the past year against the Zacks Medical - Biomedical and Genetics industry's decline of -16.1%. The company beat first-quarter estimates for both earnings and sales. Key medicines like Evenity, Repatha and Blincyto -- as well as newer medicines like Tavneos and Tezspire -- are driving sales, more than offsetting declining revenues from oncology biosimilars and legacy established products like Enbrel.
New biosimilar launches are expected to contribute to top-line growth. Amgen also has some key pipeline assets in obesity and inflammation. However, increased pricing headwinds and competitive pressure are hurting sales of many products.
Weakness in some key brands like Otezla and Lumakras create potential revenue headwinds. Sales of best-selling drugs Prolia and Xgeva are expected to decline from the second half of 2025 due to biosimilar competition.
Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.
Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights Eli Lilly, GE Aerospace and Amgen
For Immediate Release
Chicago, IL – May 23, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Eli Lilly and Co. (LLY - Free Report) , GE Aerospace (GE - Free Report) and Amgen Inc. (AMGN - Free Report) .
Here are highlights from Thursday’s Analyst Blog:
Top Analyst Reports for Eli Lilly, GE Aerospace and Amgen
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Co., GE Aerospace and Amgen Inc.. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
Ahead of Wall Street
The daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens and attempts to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.
You can read today's AWS here >>> Pre-Markets Even Out as Investors Digest Tax Bill
Today's Featured Research Reports
Shares of Eli Lilly have declined -10.9% over the past year versus the Zacks Large Cap Pharmaceuticals industry's decline of -14.7%. The company's Q1 earnings missed estimates while sales beat. Demand for popular GLP-1 drugs Mounjaro and Zepbound remains strong, making them the company's key top-line drivers.
Though sales were below expectations in the second half of 2024, they picked up in the first quarter, driven by launches of the drugs in new international markets, and improved supply from ramped-up production. In the past two years, Lilly received approvals for some new drugs like Kisunla, Omvoh and Jaypirca, which are also contributing to its top-line growth.
Lilly is also making rapid pipeline progress in obesity and diabetes. Declining sales of Trulicity, rising pricing pressure on some drugs and potential competition in the GLP-1 diabetes/obesity market are some top-line headwinds.
(You can read the full research report on Eli Lilly here >>>)
GE Aerospace's shares have outperformed the Zacks Aerospace - Defense industry over the past year (+41.3% vs. +12.9%). The company has been witnessing strength in its businesses, driven by robust demand for commercial engines, propulsion and additive technologies. Rising U.S. & international defense budgets, geopolitical tensions, positive airline & airframer dynamics and robust demand for commercial air travel augur well for the company.
Portfolio-reshaping actions are likely to unlock values for its shareholders. The company raised its dividend by 28.6% to 36 cents per share in February 2025. For 2025, GE Aerospace expects organic revenues to grow in the low-double-digit range from the year-ago level.
However, it has been dealing with high costs and expenses related to certain projects and restructuring activities, which are likely to affect margins and profitability. Also, foreign exchange headwinds might be a concern for the company.
(You can read the full research report on GE Aerospace here >>>)
Shares of Amgen have declined -8.7% over the past year against the Zacks Medical - Biomedical and Genetics industry's decline of -16.1%. The company beat first-quarter estimates for both earnings and sales. Key medicines like Evenity, Repatha and Blincyto -- as well as newer medicines like Tavneos and Tezspire -- are driving sales, more than offsetting declining revenues from oncology biosimilars and legacy established products like Enbrel.
New biosimilar launches are expected to contribute to top-line growth. Amgen also has some key pipeline assets in obesity and inflammation. However, increased pricing headwinds and competitive pressure are hurting sales of many products.
Weakness in some key brands like Otezla and Lumakras create potential revenue headwinds. Sales of best-selling drugs Prolia and Xgeva are expected to decline from the second half of 2025 due to biosimilar competition.
(You can read the full research report on Amgen here >>>)
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.
Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.